Inicio
Detalle del título uniforme
Human Vaccines & Immunotherapeutics
Tipo de obra :
Autre
Naturaleza de la obra :
Oeuvre
|
Documentos disponibles con este título uniforme (1)
Clasificado(s) por (Año de edición descendente) Refinar búsqueda
Maternal transfer of anti HPV 6 and 11 antibodies upon immunization with the 9-valent HPV vaccine / Ana María Guevara Zambrano
Título : Maternal transfer of anti HPV 6 and 11 antibodies upon immunization with the 9-valent HPV vaccine Tipo de documento : documento electrónico Autores : Ana María Guevara Zambrano, Fecha de publicación : 2019 Títulos uniformes : Human Vaccines & Immunotherapeutics Idioma : Inglés (eng) Palabras clave : Human papillomavirus 9vHPV vaccine recurrent respiratory papillomatosis clinical trial geometric mean titers (GMTs) Resumen : Background: This exploratory analysis was conducted to characterize the level of HPV types 6/11 antibodies in peripartum maternal blood and in cord blood of infants born to women who received 9-valent HPV (9vHPV) vaccine or quadrivalent HPV (qHPV) vaccine in a pivotal efficacy study (V503-001, NCT 00543543). Methods: A total of 21 mother-infant pairs had evaluable HPV 6/11 results available for analysis. HPV6/11 antibodies were assessed using competitive Luminex immunoassay. The distribution of the ratios of infant to mother anti-HPV antibodies (i.e., infant-anti-HPV/mother- anti-HPV) was summarized. Results: All mothers and infants were seropositive to HPV 6 and HPV 11. Anti-HPV 6/11 geometric mean titers (GMTs) in peripartum maternal blood and in cord blood of infant born to study participants were highly correlated. A 100% of infants born to seropositive mothers were also seropositive. The GMT ratios of peripartum maternal blood vs. those in cord blood were HPV 6: 1.23 [0.43, 3.49] and HPV 11: 1.29 [0.54, 3.07] in the 9vHPV vaccine group and HPV 6: 1.33 [0.41, 4.29] and HPV 11: 1.19 [0.45, 3.13] in the qHPV vaccine group, respectively. Conclusions: These results indicate that antibodies induced by the 9vHPV vaccine cross the placenta, which could potentially be beneficial against HPV6/11 infection and related disease such as recurrent respiratory papillomatosis. Mención de responsabilidad : Ana Maria Guevara, Eugenio Suarez, Alejandro Victoria, Hextan Ys Ngan, Angelica Lindén Hirschberg, Edison Fedrizzi, Oliver Bautista, Christine Shields, Amita Joshi, Alain Luxembourg Referencia : Hum Vaccin Immunother. 2019;15(1):141-145. DOI (Digital Object Identifier) : 10.1080/21645515.2018.1514227 PMID : 30261146 En línea : https://www.tandfonline.com/doi/abs/10.1080/21645515.2018.1514227?journalCode=kh [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4174 Maternal transfer of anti HPV 6 and 11 antibodies upon immunization with the 9-valent HPV vaccine [documento electrónico] / Ana María Guevara Zambrano, . - 2019.
Obra : Human Vaccines & Immunotherapeutics
Idioma : Inglés (eng)
Palabras clave : Human papillomavirus 9vHPV vaccine recurrent respiratory papillomatosis clinical trial geometric mean titers (GMTs) Resumen : Background: This exploratory analysis was conducted to characterize the level of HPV types 6/11 antibodies in peripartum maternal blood and in cord blood of infants born to women who received 9-valent HPV (9vHPV) vaccine or quadrivalent HPV (qHPV) vaccine in a pivotal efficacy study (V503-001, NCT 00543543). Methods: A total of 21 mother-infant pairs had evaluable HPV 6/11 results available for analysis. HPV6/11 antibodies were assessed using competitive Luminex immunoassay. The distribution of the ratios of infant to mother anti-HPV antibodies (i.e., infant-anti-HPV/mother- anti-HPV) was summarized. Results: All mothers and infants were seropositive to HPV 6 and HPV 11. Anti-HPV 6/11 geometric mean titers (GMTs) in peripartum maternal blood and in cord blood of infant born to study participants were highly correlated. A 100% of infants born to seropositive mothers were also seropositive. The GMT ratios of peripartum maternal blood vs. those in cord blood were HPV 6: 1.23 [0.43, 3.49] and HPV 11: 1.29 [0.54, 3.07] in the 9vHPV vaccine group and HPV 6: 1.33 [0.41, 4.29] and HPV 11: 1.19 [0.45, 3.13] in the qHPV vaccine group, respectively. Conclusions: These results indicate that antibodies induced by the 9vHPV vaccine cross the placenta, which could potentially be beneficial against HPV6/11 infection and related disease such as recurrent respiratory papillomatosis. Mención de responsabilidad : Ana Maria Guevara, Eugenio Suarez, Alejandro Victoria, Hextan Ys Ngan, Angelica Lindén Hirschberg, Edison Fedrizzi, Oliver Bautista, Christine Shields, Amita Joshi, Alain Luxembourg Referencia : Hum Vaccin Immunother. 2019;15(1):141-145. DOI (Digital Object Identifier) : 10.1080/21645515.2018.1514227 PMID : 30261146 En línea : https://www.tandfonline.com/doi/abs/10.1080/21645515.2018.1514227?journalCode=kh [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4174 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000788 AC-2018-075 Archivo digital Producción Científica Artículos científicos Disponible